MannKind Corporation MNKD
-
Why Mannkind Has Long-Term Value
By Spencer Knight : Buying a beat down biotech stock, such as Mannkind ( MNKD ), requires patience more than anything else; except for the obvious due diligence. Mannkind is most well known for the firm …
-
New Morningstar Analyst Report - MannKind Corporation
MannKind received another complete response letter for Afrezza. With a rising debt load and only early-stage drugs remaining in its pipeline, shareholders are likely to be left empty-handed if MannKind is unable to meet agency demands.Even if Afrezza succeeds in gaining approval, the product could
-
MannKind's CEO Discusses Q1 2012 Results - Earnings Call Transcript
MannKind ( MNKD ) Q1 2012 Earnings Call May 09, 2012 5:00 pm ET Executives Matthew ..... Ladies and gentlemen, thank you for standing by. Welcome to the MannKind Corporation First Quarter 2012 Conference Call. [Operator Instructions] As …
-
Premarket gainers: [[BKS]] +92%. [[DMD]] +38%. [[SUN]] +21%. [[WCRX]] +20%. [[GPRO]] +20%. [[XOMA]] +9%. [[IOC]] +5%. [[ MNKD ]] +5%. [[PLX]] +4%. [[ARNA]] +4%. [[AMRN]] +3%.Losers: [[LDK]] -14%. ...
Premarket gainers: BKS +92% . DMD +38% . SUN +21% . WCRX +20% . GPRO +20% . XOMA +9% . IOC +5% . MNKD +5% . PLX +4% . ARNA +4% . AMRN +3% . Losers: LDK -14% . SOHU -8% . GNC -5% . HUM -5% . HOLX -4% . SINA -3% . Post your comment!
-
Biotech-Focused Star Hedge Fund Tang Capital's Q1 2012 Picks In Its $429 Million Portfolio
By Ganaxi Small Cap Movers : San Diego, CA-based Tang Capital Management, founded in 2002 by Kevin C. Tang is a hedge fund that specializes in the life sciences industry. Prior to founding his firm, Mr. Tang was most recently the Managing Director and head of Life Sciences research group at ...
-
MannKind: Will The Good News Ever Come?
By Douglas W. House : In my opinion, biotech stands out as the most difficult industry in which to consistently make money in. Sky-high multiples, billion dollar valuations for companies with no sales, white-knuckle price swings and a plethora of unrealized dreams have been the norm for many years.
-
Biodel Back At Square One, Not Zero
By Stephen Simpson : Like many other biopharmas taking on the diabetes market, Biodel ( BIOD ) has had pretty serious setbacks. The decision to abandon the original Linjeta absolutely hammered the stock, and it is true that the company is a very speculative stock at this point. That said, with a ...
-
9 Healthcare Stocks With Major Catalysts Due in April
By Spencer Knight : After a very busy month of March, April will not be any easier for the FDA. There will be seven events in April that will involve five small cap biotech companies as well as four large cap healthcare firms. Per the usual, small cap biotech stocks are made or broken when FDA ...
-
Small-Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
By Ganaxi Small Cap Movers : The biotech group as represented by the NYSE ARCA Biotech Index ($BTK) has been strong this year, now up over 27% YTD, and still trending higher. With both the market and the biotech sector in strong bull mode, now maybe an opportune time to go 'shop' for biotech ...
-
Cytori Is A Compelling Short Sale Opportunity
By Martin Shkreli : The book value of Cytori ( CYTX ) common stock is $0.18 per share as of Q4 2011, and I project it will be close to zero at the end of Q1 2012. Unfortunately for Cytori shareholders, book value approximates what I believe is fair value of the equity. What should one pay for a ...